News from the healthcare data industry
22 Mar 2022 Francesca Bruce@ScripFrancesca Francesca.bruce@informa.com Executive Summary England’s health technology appraisal body, NICE, will publish a framework that will help it deliver on its ambition to use real-world evidence to...
WASHINGTON—Today, the U.S. Senate Health, Education, Labor, and Pension (HELP) Committee advanced the PREVENT Pandemics Act, which includes seven bills and additional provisions led by U.S. Senator Bill Cassidy, M.D. (R-LA). Dr. Cassidy’s...
Advanced techniques for generating real-world evidence (RWE) help pharmaceutical companies deliver insights that transform outcomes for patients—and create significant value. McKinsey estimates that over the next three to five years, an average top-20...
When inspecting clinical trials that incorporate real-world data, the UK medicines regulator says that its good clinical practice (GCP) inspectors expects sponsors to be able to demonstrate that the RWD...
Matthew W. Reynolds, Vice President, Real World Solutions, IQVIA 03.09.22Recent FDA guidance on using real world data (RWD) to study the safety and effectiveness of products and treatments represents an exciting advancement for...
Report Prepared by the Oncology Industry Taskforce RWE Working Group, a Medicines Australia Initiative Read the Report here: https://www.medicinesaustralia.com.au/wp-content/uploads/sites/65/2020/11/OIT-RWE-Report-Oct-2020-FINAL-MA-VERSION.pdf
Background: Abiraterone and enzalutamide are widely used as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC); however, their efficacy in mCRPC has been inconsistently demonstrated in other outcome studies from real-world...
Newswise — Lawrenceville, NJ, USA—March 8, 2022—ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) in partnership with the Bristol Myers Squibb-Pfizer Alliance announced that it has launched a...
Abstract Osteoarthritis is a degenerative joint disease that affects millions of people worldwide. Current guidelines emphasize the importance of regular physical activity as a preventive measure against disease progression and...
Treatment with eribulin (Halaven) elicited an estimated 2-year overall survival (OS) rate of 53.6% (95% CI, 35.1%-68.9%) for patients with metastatic breast cancer (MBC) previously treated with atezolizumab (Tecentriq) or...